Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease

Archive ouverte

Lai, Dongbing | Alipanahi, Babak | Fontanillas, Pierre | Schwantes‐an, Tae‐hwi | Aasly, Jan | Alcalay, Roy, N | Beecham, Gary, W | Berg, Daniela | Bressman, Susan | Brice, Alexis | Brockman, Kathrin | Clark, Lorraine | Cookson, Mark | Das, Sayantan | van Deerlin, Vivianna | Follett, Jordan | Farrer, Matthew, J | Trinh, Joanne | Gasser, Thomas | Goldwurm, Stefano | Gustavsson, Emil | Klein, Christine | Lang, Anthony, E | Langston, J, William | Latourelle, Jeanne | Lynch, Timothy | Marder, Karen | Marras, Connie | Martin, Eden, R | Mclean, Cory, Y | Mejia‐santana, Helen | Molho, Eric | Myers, Richard, H | Nuytemans, Karen | Ozelius, Laurie | Payami, Haydeh | Raymond, Deborah | Rogaeva, Ekaterina | Rogers, Michael, P | Ross, Owen, A | Samii, Ali | Saunders‐pullman, Rachel | Schüle, Birgitt | Schulte, Claudia | Scott, William, K | Tanner, Caroline | Tolosa, Eduardo | Tomkins, James, E | Vilas, Dolores | Trojanowski, John, Q | Uitti, Ryan | Vance, Jeffery, M | Visanji, Naomi, P | Wszolek, Zbigniew, K | Zabetian, Cyrus, P | Mirelman, Anat | Giladi, Nir | Orr Urtreger, Avi | Cannon, Paul | Fiske, Brian | Foroud, Tatiana

Edité par CCSD ; Wiley -

International audience. Objective: The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age-at-onset of Parkinson's disease.Methods: We performed the first genomewide association study of penetrance and age-at-onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non-cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age-at-onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age-at-onset in LRRK2 mutation carriers.Results: A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E-08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co-immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E-07; age-at-onset top variant: p value = 9.3E-07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age-at-onset.Interpretation: This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82-94.

Suggestions

Du même auteur

Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

Archive ouverte | Vollstedt, Eva‐juliane | CCSD

International audience. Background: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is impera...

Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry

Archive ouverte | Lee, Annie | CCSD

International audience. BackgroundPenetrance estimates of the LRRK2 p.G2019S mutation for Parkinson’s disease (PD) vary widely (24%–100%). The p.G2019S penetrance in individuals of Ashkenazi Jewish ancestry has been...

Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance

Archive ouverte | San Luciano, Marta | CCSD

International audience. Abstract Background The penetrance of leucine rich repeat kinase 2 ( LRRK2 ) mutations is incomplete and may be influenced by environmental and/or other genetic factors. Nonsteroidal anti‐inf...

Chargement des enrichissements...